dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Kultuuriministeerium
Sissetulev kiriAvalik

Kiri

Kultuuriministeerium · 18. november 2019
Viit
9-5/2043-1
Registreeritud
18. november 2019
Dokumendi liik
Sissetulev kiri
Adressaat
UNESCO
Saabumis/saatmisviis
e-post
Funktsioon
9 Välisesinduste ning rahvusvahelise koostöö korraldamine
Sari
9-5 Kirjavahetus Rahvusvaheliste organisatsioonidega (Euroopa Nõukogu, UNESCO jms)
Toimik
9-5/2019 Kirjavahetus Rahvusvaheliste organisatsioonidega (Euroopa Nõukogu, UNESCO jms)
Vastutaja
Kadri Jauram
Lahendamise tähtaeg
18. detsember 2019

Failid

  • 📎DG 2nd letter notification_Prohibited List 2020.pdf54 KB
  • 📎InternationalStandard_2020 ProhibitedList_ENGLISH- Clean-Final.pdf175 KB

Sisu (failidest)

The World Anti-Doping Code THE 2020 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2020 THE 2020 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2020 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) when administered exogenously, including but not limited to: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-androstenedione (5α-androst-1-ene-3,17-dione); 1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one); The 2020 Prohibited List 23 September 2019 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-androstenediol (androst-4-ene-3β,17β-diol); 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); 5-androstenedione (androst-5-ene-3,17-dione); 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; 7-keto-DHEA; 19-norandrostenediol (estr-4-ene-3,17-diol); 19-norandrostenedione (estr-4-ene-3,17-dione); androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-androstan-3-one); androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol and 17α- methyl-5α-androst-3-en-17β-ol); drostanolone; epiandrosterone (3β-hydroxy-5α-androstan-17-one); epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3-one); epitestosterone; ethylestrenol (19-norpregna-4-en-17α-ol); fluoxymesterone; formebolone; furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); gestrinone; mestanolone; mesterolone; metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); metenolone; methandriol; methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylclostebol; methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3- one); mibolerone; nandrolone (19-nortestosterone); norboletone; The 2020 Prohibited List 23 September 2019 norclostebol (4-chloro-17β-ol-estr-4-en-3-one); norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α- androstane); quinbolone; stanozolol; stenbolone; testosterone; tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien- 3-one); trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 2. Other Anabolic Agents Including, but not limited to: Clenbuterol, selective androgen receptor modulators [SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm (ostarine) and RAD140], tibolone, zeranol and zilpaterol. S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to: 1.1 Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO- mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. Cobalt; daprodustat (GSK1278863); molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. The 2020 Prohibited List 23 September 2019 1.3 GATA inhibitors, e.g. K-11706. 1.4 TGF-beta (TGF-β) signalling inhibitors, e.g. Luspatercept; sotatercept. 1.5 Innate repair receptor agonists, e.g. Asialo EPO; carbamylated EPO (CEPO). 2. Peptide Hormones and their Releasing Factors, : 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin; 2.2 Corticotrophins and their releasing factors, e.g. Corticorelin; 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin). 3. Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF); and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. The 2020 Prohibited List 23 September 2019 S3. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited; Including, but not limited to: Fenoterol; formoterol; higenamine; indacaterol; olodaterol; procaterol; reproterol; salbutamol; salmeterol; terbutaline; tretoquinol (trimetoquinol); tulobuterol; vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. S4. HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 2-Androstenol (5α-androst-2-en-17-ol); 2-androstenone (5α-androst-2-en-17-one); 3-androstenol (5α-androst-3-en-17-ol); 3-androstenone (5α-androst-3-en-17-one); 4-androstene-3,6,17 trione (6-oxo); aminoglutethimide; anastrozole; androsta-1,4,6-triene-3,17-dione (androstatrienedione); The 2020 Prohibited List 23 September 2019 androsta-3,5-diene-7,17-dione (arimistane); exemestane; formestane; letrozole; testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Bazedoxifene; ospemifene; raloxifene; tamoxifen; toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomifene; cyclofenil; fulvestrant. 4. Agents preventing activin receptor IIB activation including, but not limited, to: Activin A-neutralizing antibodies; activin receptor IIB competitors such as decoy activin receptors (e.g. ACE-031); anti-activin receptor IIB antibodies (e.g. bimagrumab); myostatin inhibitors such as agents reducing or ablating myostatin expression; myostatin-neutralizing antibodies (e.g. domagrozumab, landogrozumab, stamulumab); myostatin-binding proteins (e.g. follistatin, myostatin propeptide). 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2- (4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; The 2020 Prohibited List 23 September 2019 5.3 Meldonium; 5.4 Trimetazidine. S5. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide). • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. The 2020 Prohibited List 23 September 2019 PROHIBITED METHODS M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M2. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12- hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M3. GENE AND CELL DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. 2. The use of normal or genetically modified cells. The 2020 Prohibited List 23 September 2019 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the classes S0 to S5 and M1 to M3 defined above, the following classes are prohibited In-Competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; amfepramone; amfetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4-phenylpiracetam (carphedon)]; furfenorex; lisdexamfetamine; mefenorex; mephentermine; mesocarb; metamfetamine(d-); p-methylamfetamine; modafinil; The 2020 Prohibited List 23 September 2019 norfenfluramine; phendimetrazine; phentermine; prenylamine; prolintane. A stimulant not expressly listed in this section is a Specified Substance. b: Specified Stimulants: Including, but not limited to: 3-Methylhexan-2-amine (1,2-dimethylpentylamine); 4-methylhexan-2-amine (methylhexaneamine); 4-methylpentan-2-amine (1,3-dimethylbutylamine); 5-methylhexan-2-amine (1,4-dimethylpentylamine); benzfetamine; cathine**; cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; dimetamfetamine (dimethylamphetamine); ephedrine***; epinephrine**** (adrenaline); etamivan; etilamfetamine; etilefrine; famprofazone; fenbutrazate; fencamfamin; heptaminol; hydroxyamfetamine (parahydroxyamphetamine); isometheptene; levmetamfetamine; meclofenoxate; methylenedioxymethamphetamine; methylephedrine***; methylphenidate; nikethamide; norfenefrine; octodrine (1,5-dimethylhexylamine); octopamine; oxilofrine (methylsynephrine); pemoline; pentetrazol; phenethylamine and its derivatives; phenmetrazine; phenpromethamine; The 2020 Prohibited List 23 September 2019 propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine); tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine • Imidazole derivatives for dermatological, nasal or ophthalmic use and those stimulants included in the 2020 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2020 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. S7. NARCOTICS The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited: Buprenorphine; dextromoramide; diamorphine (heroin); fentanyl and its derivatives; hydromorphone; methadone; morphine; nicomorphine; oxycodone; oxymorphone; The 2020 Prohibited List 23 September 2019 pentazocine; pethidine. S8. CANNABINOIDS All natural and synthetic cannabinoids are prohibited, e.g.  In cannabis (hashish, marijuana) and cannabis products  Natural and synthetic tetrahydrocannabinols (THCs)  Synthetic cannabinoids that mimic the effects of THC Except: • Cannabidiol. S9. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Including but not limited to: Betamethasone; budesonide; cortisone; deflazacort; dexamethasone; fluticasone; hydrocortisone; methylprednisolone; prednisolone; prednisone; triamcinolone. The 2020 Prohibited List 23 September 2019 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; labetalol; alprenolol; metipranolol; atenolol; metoprolol; betaxolol; nadolol; bisoprolol; oxprenolol; bunolol; pindolol; carteolol; propranolol; carvedilol; sotalol; celiprolol; timolol. esmolol; The 2020 Prohibited List 23 September 2019 Thé Director-General United Nations Educational, Scientific and Cultural Organization Organisation des Nations Unies pour l'éducation, la science et la culture Organizaciôn de las Naciones Unidas To Ministers responsible for relations para la Educaciôn, with UNESCOof thé States Parties to la Ciencia y la Cultura thé International Convention against OpraHM3aL|Mfl 06-befliiHeHHbixHau,vivi no Doping in Sport BonpocaM o6pa30BaHiiH, HayK M vi KynbTypu û^-ShJAÎl /a-4^1 ^-âJaiû AilSIIj ^Ixllj A-uj^ %^Sât- ?4^AJt-ttSéR Réf. : DG/3/19/9234-1 î 5 NOV 2019 Sir/Madam, On 1 October 2019, ail States Parties to thé International Convention against Doping in Sport were notified of thé changes made by thé World Anti-Doping Agency to thé Prohibited List - International Standard (hereinafter referred to as "thé2020 Prohibited List"). States Parties were reminded that they had 45 days to express their objections to thé proposed amendments in writing. Pursuant to Article 34, paragraph 2, of thé Convention, thé amendments to Annex l reflecting thé 2020 Prohibited List Standard are approved by thé Conférence of Parties. Thèse amendments will enter into force 45 days after this notification, that is to say, on 1 January 2020, except for any State Party having notified thé UNESCO Secrétariat that it does not accept thèse amendments, in which case such State Party will remain bound by Annex l as it was prior to amendment. Thé 2020 Prohibited List cornes into effect for thé sporting movement on thé same day, on 1 January 2020. Accept, Sir/Madam, thé assurances of my highest considération. Audrey Azoulay Enc. 7, place de Fontenoy 75352 Paris 07, SP, France Tél. :+33 (0)1 45681000 Fax: +33 (0)1 45 67 55 55 www. unesco. org
Allikas: Kultuuriministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel